Prime Global Medical Communications Ltd, (“Prime Global” or the “Company”), a portfolio company of Levine Leichtman Capital Partners (“LLCP”) announced the acquisition of Aventine Consulting (“Aventine”), a U.S.-based consulting firm specialising in U.S.-focused market access and payer communications. Financial terms of the transaction were not disclosed.

Prime Global is a leader in medical communications, evidence and access, and patient engagement, with people based across the U.K., U.S., Europe, and New Zealand. The Company provides the world’s leading pharmaceutical, biotech and healthcare businesses with full-service professional communications services, including healthcare strategy and consultancy, scientific and medical communications, patient integrated science, real-world evidence (“RWE”) and health economics and outcomes research (“HEOR”), and market access.

This transaction represents the third major strategic acquisition by Prime Global in the past two years, having acquired both HCD Economics and the creative digital technology agency Earthware in 2022.

Aventine, Prime’s first U.S. acquisition, specializes in market access and payer engagement, which is one of the fastest growing areas in the pharmaceutical services sector. The transaction is expected to significantly bolster and complement Prime’s existing evidence and access proposition. As a result, the evidence and access function will include a U.S. market access presence to geographically support U.S.-based global clients. In addition, this newly expanded collaborative team is expected to be well-positioned to address the increasing needs of the U.S. domestic market to demonstrate value for payers.

In a statement, Graeme Peterson Prime’s CEO comments: “We are thrilled to be joining forces with the specialised and experienced Aventine team headed up by Boston-based Holly Trautman and Jamie Dunning out of Seattle. The acquisition will allow us to have local U.S. evidence and access expertise in a market where payer experience is key. Strategically, joining forces with Aventine further demonstrates commitment to our new vision, ‘Accelerating life-changing solutions to global healthcare challenges’. This augments our expertise in this key area, supporting the delivery of world-class outcomes for our clients, and improving lives sooner.”

Graeme adds: “Aventine will help support our U.S-based global clients as well as our U.S. domestic clients where there is a growing need to demonstrate value for payers within the healthcare system. We are excited about the prospect of collaboration between Aventine and the existing Prime Access and HCD teams, and the opportunity to overlay complementary technical solutions in health economics and real-world studies.”

Holly Trautman, COO Aventine adds: “We are eager to begin the next phase of our journey with Prime, and to draw upon the broader scientific, technical, strategic and creative expertise that Prime brings to further enhance life-changing solutions for our clients.”

Prime Global is a portfolio company of Levine Leichtman Capital Partners Europe II, SCSp.